At a glance
CDC works with partners in Nigeria to build sustainable public health capacity, strengthen laboratory systems and surveillance networks, deliver high-quality HIV and TB diagnostic, treatment, and prevention services, and respond swiftly to disease outbreaks at their source, preventing health threats from reaching the U.S.
Strategic focus
The U.S. Centers for Disease Control and Prevention (CDC) office in Nigeria was established in February 2001. CDC provides technical leadership and assistance to the Ministry of Health (MOH) and implementing partners to achieve comprehensive, sustainable, and government-led HIV programs, with the goal of reaching the UNAIDS 95-95-95 targets. CDC also supports tuberculosis (TB) services, laboratory services, health system strengthening, and workforce capacity building.
Read more about CDC's most recent key activities and accomplishments below.
Building public health capacity
- Built the clinical and program capacity of healthcare providers at the facility level and ensured quality service provision through the National Clinical Mentors Program in partnership with the National AIDS, Viral Hepatitis, and STIs Control Programme. By the end of 2024, the program had 34 national and 315 state mentors in 34 states and the Federal Capital Territory.
- Implemented the Extension for Community Health Outcomes (Project ECHO) platform. Project ECHO serves as a conduit for tele-mentoring, information sharing, and communication to improve service delivery and outbreak responses at all levels—from state health commissioners to facility healthcare workers.
- Established the National Data Repository system to eliminate challenges caused by facility level electronic medical records. CDC works with partners to establish an automated biometric identification system. Since 2023, healthcare facilities have collected fingerprints for over 1.3 million patients who receive treatment at 1,200 CDC-supported sites.
Strengthening laboratory systems and networks
- Built in-country capacity for optimized laboratory networks and improved access to quality laboratory diagnostics services, including molecular diagnostic services for HIV, TB, and associated diseases.
- Improved surveillance and strengthened response efforts for diseases of public health importance to ensure patient management decisions and public health actions are informed by evidence-based practices.
- Supported the renovation of the molecular laboratory at Federal Medical Centre Makurdi in Benue State. Testing over 200,000 samples annually, the laboratory now serves as the molecular laboratory for HIV viral load, early infant diagnosis testing, and for molecular testing of other priority diseases.
HIV prevention and treatment
- Provided HIV testing services to nearly 6.2 million people in FY2024, of which 149,244 were HIV-positive and 145,685 were linked to treatment. CDC continues to close testing and treatment gaps in pediatrics, youth and adolescents, women, and people at greater risk of HIV.
- Achieved the U.S. President’s Emergency Plan for AIDS Relief's (PEPFAR's) ‘Getting the Data Right’ initiative to verify clients and confirm the number of people receiving antiretroviral therapy (ART). At the end of 2024, approximately 931,500 people living with HIV were receiving life-saving treatment in CDC-supported states.
- Implemented the ART Impact Survey with the Government of Nigeria to understand the status of HIV programming and progress towards reaching the UNAIDS 95-95-95 targets. The survey will determine treatment coverage and viral load suppression rates in three high-burden states: Akwa Ibom, Lagos, and Rivers.
- Launched the cabotegravir long-acting injectable trial for people at greater risk of HIV.
- Supported innovative technology hubs that provide HIV-positive adolescents and young adults with HIV services, as well as vocational training to support themselves.
Tuberculosis prevention and treatment
- Rolled out a life-saving, shorter TB preventive treatment regimen known as "3HP," decreasing the treatment length from 6 to 3 months. In 2024, over 89,000 people were placed on 3HP.
- Distributed 32 portable chest X-ray machines for government facilities in CDC-supported states to strengthen TB case finding among people living with HIV.
By the numbers
HIV
Estimated HIV Prevalence (Ages 15-49)
1.3% (2023)
30,000 (2023)
Reported Number Receiving Antiretroviral Therapy (ART) (Age ≥15)
1,690,291 (2023)
TB
Estimated TB Incidence
219/100,000 population (2023)
Reported Percent of People with TB and HIV
4.9% (2023)
TB Treatment Success Rate
93% (2022)
Resources
Our success is built on the backbone of science and strong partnerships.